Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia

Abstract

PurposePediatric medulloblastoma (MB) treatment has evolved over the past few decades; however, treating children in countries with limited resources remains challenging. Until now, the literature regarding childhood MB in Malaysia has been nonexistent. Our objectives were to review the demographics and outcome of pediatric MB treated at the University Malaya Medical Center between January 1994 and December 2013 and describe the challenges encountered.MethodsFifty-one patients with childhood MB were seen at University Malaya Medical Center. Data from 43 patients were analyzed; eight patients were excluded because their families refused treatment after surgery.ResultsHeadache and vomiting were the most common presenting symptoms, and the mean interval between symptom onset and diagnosis was 4 weeks. Fourteen patients presented with metastatic disease. Five-year progression-free survival (± SE) for patients ≥ 3 years old was 41.7% ± 14.2% (95% CI, 21.3% to 81.4%) in the high-risk group and 68.6% ± 18.6% (95% CI, 40.3% to 100%) in the average-risk group, and 5-year overall survival (± SE) in these two groups was 41.7% ± 14.2% (95% CI, 21.3% to 81.4%) and 58.3% ± 18.6% (95% CI, 31.3% to 100%), respectively. Children younger than 3 years old had 5-year progression-free and overall survival rates (± SE) of 47.6% ± 12.1% (95% CI, 28.9% to 78.4%) and 45.6% ± 11.7% (95% CI, 27.6% to 75.5%), respectively. Time to relapse ranged from 4 to 132 months. Most patients who experienced relapse died within 1 year. Febrile neutropenia, hearing loss, and endocrinopathy were the most common treatment-related complications.ConclusionThe survival rate of childhood MB in Malaysia is inferior to that usually reported in the literature. We postulate that the following factors contribute to this difference: lack of a multidisciplinary neuro-oncology team, limited health care facilities, inconsistent risk assessment, insufficient data in the National Cancer Registry and pathology reports, inadequate long-term follow-up, and cultural beliefs leading to treatment abandonment.

Telemedicine in Neurological Disorders: Opportunities and Challenges

“…30 The incorrect risk stratification and the scarcity of standardized treatment protocols contribute to the different survival rates observed. 31 Of note, a study of pediatric brain tumors in India showed that over 25% of patients abandoned neuro-oncological treatments due to late diagnosis, complex multidisciplinary treatments, and lack of consistency in the management between different oncology centers. 32 Within this context, telemedicine might facilitate communication between advanced oncological centers and local primary care facilities, as demonstrated by successful initiatives in children with cancer and other catastrophic diseases conducted in low-middle income countries.…”

Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort

“…High income countries report incidence rates of 20%‐25%, whereas low to middle income countries report 6.1%‐49.4% . Diagnostic and treatment protocols vary across the world due to—among other things—financial and logistic factors . Ultimately, these inconsistencies can result in a disparity of survival rates and HRQL .…”

“…Survival rates for medulloblastoma have increased significantly due to improved treatment methods, with five year survival rates that range from 70% to 85% . However, there is a disparity in survival rates in low to middle income countries—ranging from 33% to 73% . Social, cognitive, and neurological long‐term late effects have the potential to compromise the ongoing quality of life of survivors worldwide .…”

Treatment Outcome and Prognostic Factors in Children with Medulloblastoma: A Retrospective Study of 53 Children in a Developing Country, Egypt

“…This group received definitive surgery followed by chemotherapy, which played an essential role in the treatment of this infantile group because it allowed one to delay the use of radiation for these patients, who received neoadjuvant chemotherapy and reduced the harm to the developing nervous system in this age group. 17 The most common toxicity in our studied patients was blood toxicity in the form of myelosuppression. Forty-nine patients developed grades 3 and 4 blood toxicity during treatment.…”